Plitidepsin
Also known as: AM-2282, Aplidin, Dehydrodidemnin B, NSC-683863, Plitidepsin
Source Plitidepsin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Plitidepsin (Aplidin, dehydrodidemnin B) is a marine‑derived cyclic depsipeptide approved in several jurisdictions for the treatment of relapsed/refractory multiple myeloma. It is administered by intravenous infusion and exerts antitumor activity through eEF1A inhibition.
Mechanism of Action
Binds to eukaryotic translation elongation factor 1A (eEF1A), disrupting protein synthesis and triggering apoptosis via oxidative stress and JNK pathway activation.
Routes of Administration
Goals & Uses
- Antiviral activity against SARS-CoV-2Infectious DiseaseLow
- Solid tumor treatmentOncologyLow
- COVID‑19 Antiviral TherapyInfectious DiseaseModerate
- Multiple MyelomaOncologyHigh
- Treatment of T-cell lymphomasOncologyLow
- Treatment of relapsed/refractory multiple myelomaOncologyModerate
Contraindications
- Hypersensitivity to plitidepsinAllergyHigh
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseHigh
- Severe hepatic impairmentOrganHighLiver function concerns
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Active serious infectionInfectionModerate
- Known hypersensitivity to plitidepsin or excipientsAllergyHigh
Adverse Effects
- Peripheral neuropathyNeurologicalUncommon
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- Elevated transaminasesHepaticCommon
- Hematologic toxicity (neutropenia, thrombocytopenia)HematologicCommon
- Nausea and vomitingGastrointestinalCommon
- NeutropeniaHematologicCommonLow neutrophil count
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- Fatigue/astheniaGeneralCommon
- Myopathy/myalgiaMusculoskeletalCommon
Drug Interactions
- CYP3A4 inducers (e.g., rifampin)Moderate
- Myelosuppressive agents (e.g., cyclophosphamide)Moderate
- DexamethasoneLow
- Strong CYP3A4 inhibitors (e.g., ketoconazole)High
- P-glycoprotein (P-gp) substrates/inhibitorsModerate
- CYP3A4 inducers (e.g., rifampicin, carbamazepine)Moderate
- CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)High
Population Constraints
- Pediatric patientsAgeRelative
- Patients with hepatic impairmentOrgan FunctionRelative
- Elderly patients (≥75 years)AgeRelative
- Pregnant or breastfeeding womenReproductiveAbsolute
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- AUApprovedApproved: relapsed/refractory multiple myelomaApproved by TGA under brand Aplidin.
- European UnionUnapprovedNot granted marketing authorization; under evaluation.
- United StatesUnapprovedInvestigational; clinical trials ongoing.
- United KingdomUnknownNo MHRA approval documented; status follows EU investigational classification post-Brexit.
Approved in Australia (TGA) for multiple myeloma; not approved in the United States or European Union, where it remains investigational.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Plitidepsin?
Plitidepsin (Aplidin, dehydrodidemnin B) is a marine‑derived cyclic depsipeptide approved in several jurisdictions for the treatment of relapsed/refractory multiple myeloma. It is administered by intravenous infusion and exerts antitumor activity through eEF1A inhibition.
What is Plitidepsin used for?
Plitidepsin is educationally associated with: Antiviral activity against SARS-CoV-2, Solid tumor treatment, COVID‑19 Antiviral Therapy, Multiple Myeloma, Treatment of T-cell lymphomas, Treatment of relapsed/refractory multiple myeloma. Educational only — not medical advice.
How is Plitidepsin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Plitidepsin?
Reported adverse effects include: Peripheral neuropathy, Hepatotoxicity, Elevated transaminases, Hematologic toxicity (neutropenia, thrombocytopenia), Nausea and vomiting, Neutropenia, Nausea, Fatigue, Vomiting, Fatigue/asthenia, Myopathy/myalgia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Plitidepsin?
Recorded contraindications: Hypersensitivity to plitidepsin, Severe hepatic impairment (Child‑Pugh C), Severe hepatic impairment, Severe renal impairment, Pregnancy, Active serious infection, Known hypersensitivity to plitidepsin or excipients. Consult a qualified clinician before use.